238 related articles for article (PubMed ID: 10531185)
1. Continuous intravenous epoprostenol therapy for pulmonary hypertension in Gaucher's disease.
Bakst AE; Gaine SP; Rubin LJ
Chest; 1999 Oct; 116(4):1127-9. PubMed ID: 10531185
[TBL] [Abstract][Full Text] [Related]
2. IV epoprostenol in Gaucher's disease.
Elstein D; Zimran A
Chest; 2000 Jun; 117(6):1821. PubMed ID: 10858430
[No Abstract] [Full Text] [Related]
3. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis.
Humbert M; Maître S; Capron F; Rain B; Musset D; Simonneau G
Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1681-5. PubMed ID: 9603154
[TBL] [Abstract][Full Text] [Related]
4. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.
Badesch DB; Tapson VF; McGoon MD; Brundage BH; Rubin LJ; Wigley FM; Rich S; Barst RJ; Barrett PS; Kral KM; Jöbsis MM; Loyd JE; Murali S; Frost A; Girgis R; Bourge RC; Ralph DD; Elliott CG; Hill NS; Langleben D; Schilz RJ; McLaughlin VV; Robbins IM; Groves BM; Shapiro S; Medsger TA
Ann Intern Med; 2000 Mar; 132(6):425-34. PubMed ID: 10733441
[TBL] [Abstract][Full Text] [Related]
5. Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension.
McLaughlin VV; Palevsky HI
Clin Chest Med; 2013 Dec; 34(4):825-40. PubMed ID: 24267307
[TBL] [Abstract][Full Text] [Related]
6. Transition from IV to subcutaneous prostacyclin: premature withdrawal?
Shapiro S; Hill NS
Chest; 2007 Sep; 132(3):741-3. PubMed ID: 17873184
[No Abstract] [Full Text] [Related]
7. [Transition from intravenous to subcutaneous prostacyclin in pulmonary hypertension].
Escribano Subías P; Cea-Calvo L; Tello de Menesses R; Gómez Sánchez MA; Delgado Jiménez JF; Sáenz de la Calzada C
Rev Esp Cardiol; 2003 Aug; 56(8):818-21. PubMed ID: 12892628
[TBL] [Abstract][Full Text] [Related]
8. Epoprostenol sodium for treatment of pulmonary arterial hypertension.
Saito Y; Nakamura K; Akagi S; Sarashina T; Ejiri K; Miura A; Ogawa A; Matsubara H; Ito H
Vasc Health Risk Manag; 2015; 11():265-70. PubMed ID: 25999730
[TBL] [Abstract][Full Text] [Related]
9. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension.
Nagaya N; Sasaki N; Ando M; Ogino H; Sakamaki F; Kyotani S; Nakanishi N
Chest; 2003 Feb; 123(2):338-43. PubMed ID: 12576349
[TBL] [Abstract][Full Text] [Related]
10. Infections by gram-negative bacilli in patients with pulmonary arterial hypertension treated with intravenous prostacyclin.
Gómez Sánchez MA
Arch Bronconeumol; 2013 Mar; 49(3):128-9. PubMed ID: 23127721
[No Abstract] [Full Text] [Related]
11. Bloodstream infections due to Micrococcus spp and intravenous epoprostenol.
Valdivia-Arenas MA
Infect Control Hosp Epidemiol; 2009 Dec; 30(12):1237. PubMed ID: 19888847
[No Abstract] [Full Text] [Related]
12. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension.
Kuo PC; Johnson LB; Plotkin JS; Howell CD; Bartlett ST; Rubin LJ
Transplantation; 1997 Feb; 63(4):604-6. PubMed ID: 9047158
[TBL] [Abstract][Full Text] [Related]
13. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension.
Aguilar RV; Farber HW
Am J Respir Crit Care Med; 2000 Nov; 162(5):1846-50. PubMed ID: 11069824
[TBL] [Abstract][Full Text] [Related]
14. [Prostacyclin and iloprost in aerosol form in severe pulmonary hypertension].
Olschewski H; Walmrath D; Schermuly R; Ghofrani HA; Grimminger F; Seeger W
Pneumologie; 1998 Jan; 52(1):3-7. PubMed ID: 9540363
[No Abstract] [Full Text] [Related]
15. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol.
Frost AE; Quiñones MA; Zoghbi WA; Noon GP
J Heart Lung Transplant; 2005 Apr; 24(4):501-3. PubMed ID: 15797757
[TBL] [Abstract][Full Text] [Related]
16. Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension.
Kähler CM; Graziadei I; Wiedermann CJ; Kneussl MP; Vogel W
Wien Klin Wochenschr; 2000 Jul; 112(14):637-40. PubMed ID: 11008327
[TBL] [Abstract][Full Text] [Related]
17. Plasma brain natriuretic peptide as a parameter to assess efficacy of continuous intravenous infusion of prostacyclin (epoprostenol) to treat severe primary pulmonary hypertension: a case report.
Wakaumi M; Shiga T; Nozaki K; Fujiu K; Shimaya K; Ishizuka N; Matsuda N; Kasanuki H
Heart Vessels; 2000; 15(3):144-6. PubMed ID: 11289503
[TBL] [Abstract][Full Text] [Related]
18. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil.
Ivy DD; Claussen L; Doran A
Am J Cardiol; 2007 Mar; 99(5):696-8. PubMed ID: 17317374
[TBL] [Abstract][Full Text] [Related]
19. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan.
Ivy DD; Doran A; Claussen L; Bingaman D; Yetman A
Am J Cardiol; 2004 Apr; 93(7):943-6. PubMed ID: 15050507
[TBL] [Abstract][Full Text] [Related]
20. Effects of continuous intravenous epoprostenol therapy on advanced primary pulmonary hypertension in Taiwanese patients.
Hsu HH; Chen JS; Kuo SH; Chiang FT; Ko WJ; Kuo SW; Huang SC; Lee YC
J Formos Med Assoc; 2005 Jan; 104(1):60-3. PubMed ID: 15660181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
